Kozminski P, Halik P, Chesori R, Gniazdowska E
Int J Mol Sci. 2020; 21(10).
PMID: 32423175
PMC: 7279024.
DOI: 10.3390/ijms21103483.
Pai M, DeBacker K, Derstine B, Sullivan J, Su G, Wang S
Pharmacotherapy. 2020; 40(4):308-319.
PMID: 32090349
PMC: 8855476.
DOI: 10.1002/phar.2379.
Creason G, Gonzales R
Plant Cell Rep. 2013; 7(3):182-5.
PMID: 24241594
DOI: 10.1007/BF00269318.
Green J
Ther Clin Risk Manag. 2012; 8:403-13.
PMID: 23209370
PMC: 3511185.
DOI: 10.2147/TCRM.S30135.
Bussanich M, Rootman J, Kumi C, Gudauskas G
Can Vet J. 1985; 26(9):263-6.
PMID: 17422568
PMC: 1680102.
Protection and rescue from 2',3'-dideoxypyrimidine nucleoside analog toxicity by hemin in human bone marrow progenitor cells.
Fowler D, Xie M, Sommadossi J
Antimicrob Agents Chemother. 1996; 40(1):191-5.
PMID: 8787904
PMC: 163081.
DOI: 10.1128/AAC.40.1.191.
Reduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorin.
Rowland A, Pietersz G
Cancer Immunol Immunother. 1994; 39(2):135-9.
PMID: 8044832
PMC: 11038524.
DOI: 10.1007/BF01525319.
Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
Lena N, Imbert A, Pignon T, Favre R, Meyer G, Cano J
Cancer Chemother Pharmacol. 1984; 12(2):120-4.
PMID: 6697425
DOI: 10.1007/BF00254603.
The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.
Tattersall M
Br J Cancer. 1973; 27(5):406-8.
PMID: 4576563
PMC: 2008802.
DOI: 10.1038/bjc.1973.49.
Intra-arterial infusion with methotrexate in the rat.
Sindram P, Snow G, van Putten L
Br J Cancer. 1974; 30(4):349-54.
PMID: 4548653
PMC: 2009300.
DOI: 10.1038/bjc.1974.204.
The variability of individual tolerance to methotrexate in cancer patients.
Hansen H, SELAWRY O, HOLLAND J, MCCALL C
Br J Cancer. 1971; 25(2):298-305.
PMID: 4256007
PMC: 2008449.
DOI: 10.1038/bjc.1971.38.
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity.
Sommadossi J, Carlisle R, Schinazi R, Zhou Z
Antimicrob Agents Chemother. 1988; 32(7):997-1001.
PMID: 3190201
PMC: 172332.
DOI: 10.1128/AAC.32.7.997.
A pharmacokinetic model for high-dose methotrexate infusions in man.
Reich S, Bachur N, Goebel R, Berman M
J Pharmacokinet Biopharm. 1977; 5(5):421-33.
PMID: 925879
DOI: 10.1007/BF01061726.
Serum, tear and salivary concentrations of methotrexate in man.
Steele W, Stuart J, Whiting B, Lawrence J, Calman K, McVie J
Br J Clin Pharmacol. 1979; 7(2):207-11.
PMID: 760754
PMC: 1429434.
DOI: 10.1111/j.1365-2125.1979.tb00923.x.
Mathematical modeling -- guide to high-dose methotrexate infusion therapy.
Reich S
Cancer Chemother Pharmacol. 1979; 3(1):25-31.
PMID: 535126
DOI: 10.1007/BF00254416.
The protein binding of methotrexate by the serum of normal subjects.
Steele W, Lawrence J, Stuart J, McNeill C
Eur J Clin Pharmacol. 1979; 15(5):363-6.
PMID: 456408
DOI: 10.1007/BF00558441.
High-dose methotrexate with citrovorum factor rescue in non-small-cell lung cancer.
Greco F, Fer M, Richardson R, Hande K, van Boxtel C, Oldham R
Cancer Chemother Pharmacol. 1978; 1(4):255-7.
PMID: 373922
DOI: 10.1007/BF00257159.
Clinical pharmacokinetics of methotrexate.
Shen D, AZARNOFF D
Clin Pharmacokinet. 1978; 3(1):1-13.
PMID: 346283
DOI: 10.2165/00003088-197803010-00001.
Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin.
Albrecht A, Boldizsar E, Hutchison D
J Bacteriol. 1978; 134(2):506-13.
PMID: 26657
PMC: 222280.
DOI: 10.1128/jb.134.2.506-513.1978.
